NCT06886724尚未招募不适用
A Study on the Role of Ligilactobacillus Salivarius LS97 in Modulating Gut Microbiota and Immune System Function
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 尚未招募
- 入组人数
- 40
- 试验地点
- 1
- 主要终点
- Change in the composition of fecal microbiota before and after intervention.
研究概览
简要总结
Evaluate the effectiveness and safety of Ligilactobacillus salivarius LS97 as a food supplement compared to a placebo in improving intestinal and immune functions in healthy adults.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Willing to undergo 3 follow-up visits during the intervention period
- •Be willing to provide blood, urine and stool samples 2 times during the intervention period
- •Good eyesight, can read and write, can wear glasses
- •Have good hearing and be able to hear and understand all instructions during the intervention
排除标准
- •Digestive diseases, mainly gastrointestinal diseases (celiac disease, ulcerative colitis, Crohn's disease)
- •Have a serious neurological condition (epilepsy, stroke, severe head trauma, meningitis in the last 10 years, brain surgery, brain tumor prolonged coma - not including general anaesthesia)
- •Have received/are receiving treatment for the following mental disorders: alcohol/drug/substance abuse dependence, schizophrenia psychosis, bipolar disorder
- •Take medication for depression or low mood
- •Internal organ failure (heart, liver or kidney failure, etc.)
- •Have received radiation or chemotherapy in the past
- •have undergone a general anesthesia procedure/procedure within the past three years, or plan to undergo a general anesthesia procedure/procedure within the next 3 months during this trial period
- •Have had hepatitis (hepatitis B, hepatitis C), HIV or syphilis in the past
研究组 & 干预措施
Placebo group
Placebo Comparator
Every day to give 3 g maltodextrin intervention for 8 weeks.
干预措施: Placebo (Dietary Supplement)
Probiotic group
Active Comparator
Intervention with Ligilactobacillus salivarius LS97 (30 billion CFU/day, 3g) was administered daily for 8 weeks.
干预措施: Probiotic (Dietary Supplement)
结局指标
主要结局
Change in the composition of fecal microbiota before and after intervention.
时间窗: Week 0 and Week 8
Analyzed by 16S rRNA sequencing.
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Research on the Improvement of Intestinal and Immune Functions by ProbioticsIntestinal HealthNCT06873425Wecare Probiotics Co., Ltd.40
已完成
不适用
The Effect of Supplementation With Species of Lactobacillus on Anthropometric MeasurementsOverweight and ObesityNCT02448940Urmia University of Medical Sciences72
已完成
不适用
The Effect of Probiotics on the Improvement of Intestinal and Immune FunctionIntestinal and Immune Function ImprovedNCT06873438Wecare Probiotics Co., Ltd.52
Unknown
不适用
Ligilactobacillus Salivarius MP101 for Elderly in a Nursing HomeCovid19NCT04922918Universidad Complutense de Madrid25
招募中
不适用
Clinical Effects of Limosilactobacillus Reuteri Probiotics as an Adjunct to the Treatment of PeriodontitisChronic Periodontitis, GeneralizedNCT05734274Universidade do Porto60